Biocon Ltd.
NSE: BIOCON · Pharmaceuticals
Snapshot
Unlock Biocon Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Biocon Limited is a global biopharmaceutical company focused on the development and manufacturing of generics, novel biologics, and biosimilars. The company provides integrated discovery and development services across therapeutic areas including diabetes, oncology, and immunology.
Business Model
The company generates revenue through a diversified portfolio of pharmaceutical products and contract research services. It operates across four primary segments: Generics, Novel Biologics, Biosimilars, and Research Services.
Growth Outlook
Growth is driven by the expansion of its biosimilars portfolio and the scaling of its integrated research and manufacturing services. The company continues to leverage its global footprint to address unmet medical needs in over 120 countries.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from global health authorities, where any failure to meet manufacturing standards could lead to product recalls or import bans.
- Pricing Pressure. Intense competition in the generics and biosimilars market may lead to significant price erosion and margin compression.
- R&D Execution. The high cost and inherent uncertainty of clinical trials pose a risk to the successful commercialisation of novel biologics.
- Intellectual Property Litigation. The company is subject to potential patent litigation from originator pharmaceutical firms, which could delay product launches or result in legal costs.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Biocon Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹16,927 Cr
TTM · consolidated
NET PROFIT
₹369 Cr
TTM · consolidated
EPS
₹2.79
TTM · consolidated
RETURN ON EQUITY
1.5%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
3.1%
TTM · consolidated
P/E
158.0x
Q4 FY26 · consolidated
EV/EBITDA
19.2x
Q4 FY26 · consolidated
EBITDA MARGIN
22.3%
TTM · consolidated
NET PROFIT MARGIN
4.4%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.4x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Biocon Ltd.BIOCON | 59,592 | 157.96 | 19.22 | 10.9% | 22.3% | 1.5% | 3.1% | +11.7% |
Aurobindo Pharma Ltd.AUROPHARMA | 74,365 | 25.66 | 12.21 | 6.1% | 21.8% | 10.3% | 15.1% | +34.3% |
Alkem Laboratories Ltd.ALKEM | 63,210 | 29.66 | 19.40 | 13.5% | 24.4% | 18.9% | 21.2% | +14.1% |
Glenmark Pharmaceuticals Ltd.GLENMARK | 58,807 | 47.39 | 12.59 | 27.5% | 29.6% | 14.7% | 20.0% | +3.7% |
Abbott India Ltd.ABBOTINDIA | 56,163 | 38.16 | 26.96 | 8.1% | 31.5% | 35.5% | 45.4% | -18.7% |
Laurus Labs Ltd.LAURUSLABS | 53,980 | 79.92 | 38.84 | 50.9% | 26.5% | 22.5% | 26.8% | +89.4% |
As of Q4 FY26
Financials
Biocon Ltd.
NSE: BIOCON · Pharmaceuticals
Snapshot
Unlock Biocon Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Biocon Limited is a global biopharmaceutical company focused on the development and manufacturing of generics, novel biologics, and biosimilars. The company provides integrated discovery and development services across therapeutic areas including diabetes, oncology, and immunology.
Business Model
The company generates revenue through a diversified portfolio of pharmaceutical products and contract research services. It operates across four primary segments: Generics, Novel Biologics, Biosimilars, and Research Services.
Growth Outlook
Growth is driven by the expansion of its biosimilars portfolio and the scaling of its integrated research and manufacturing services. The company continues to leverage its global footprint to address unmet medical needs in over 120 countries.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from global health authorities, where any failure to meet manufacturing standards could lead to product recalls or import bans.
- Pricing Pressure. Intense competition in the generics and biosimilars market may lead to significant price erosion and margin compression.
- R&D Execution. The high cost and inherent uncertainty of clinical trials pose a risk to the successful commercialisation of novel biologics.
- Intellectual Property Litigation. The company is subject to potential patent litigation from originator pharmaceutical firms, which could delay product launches or result in legal costs.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Biocon Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹16,927 Cr
TTM · consolidated
NET PROFIT
₹369 Cr
TTM · consolidated
EPS
₹2.79
TTM · consolidated
RETURN ON EQUITY
1.5%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
3.1%
TTM · consolidated
P/E
158.0x
Q4 FY26 · consolidated
EV/EBITDA
19.2x
Q4 FY26 · consolidated
EBITDA MARGIN
22.3%
TTM · consolidated
NET PROFIT MARGIN
4.4%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.4x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26